PMID- 21839908
OWN - NLM
STAT- MEDLINE
DCOM- 20111014
LR  - 20191210
IS  - 1524-4733 (Electronic)
IS  - 1098-3015 (Linking)
VI  - 14
IP  - 5 Suppl 1
DP  - 2011 Jul-Aug
TI  - Short-term therapy with enoxaparin or unfractionated heparin for venous 
      thromboembolism in hospitalized patients: utilization study and cost-minimization 
      analysis.
PG  - S89-92
LID - 10.1016/j.jval.2011.05.017 [doi]
AB  - OBJECTIVES: To evaluate the direct costs of venous thromboembolism (VTE) 
      treatment with unfractionated heparin (UFH) and low-molecular weight heparin, 
      from the institutional perspective. METHODS: This is a real-world cohort study 
      that included inpatients treated with UFH or enoxaparin for deep venous 
      thromboembolism or pulmonary embolism in a tertiary public hospital. To estimate 
      medical costs we computed the acquisition costs of drugs, supplies for 
      administration, laboratory tests, and hospitalization cost according to the 
      patient ward. RESULTS: One hundred sixty-seven patients aged 18 to 92 years were 
      studied (50 treated with UFH and 117 with enoxaparin). The median of days in use 
      of heparin was the same in both groups. Activated partial thromboplastin time was 
      monitored in 98% of patients using UFH and 56.4% using enoxaparin. 
      Nonstatistically significant differences were observed between groups in the 
      number of bleeding events (10.0% and 9.4%; P = 1.00); blood transfusion (2.0% and 
      2.6%; P = 1.00); death (8.0% and 3.4%; P = 0.24); and recurrent VTE, bleeding, or 
      death (20.0% and 14.5%; P = 0.38). Daily mean cost per patient was US$12.63 +/- 
      $4.01 for UFH and US$9.87 +/- $2.44 for enoxaparin (P < 0.001). The total costs 
      considering the mean time of use were US$88.39 and US$69.11. CONCLUSION: The 
      treatment of VTE with enoxaparin provided cost savings in a large teaching 
      hospital located in southern Brazil.
CI  - Copyright (c) 2011 International Society for Pharmacoeconomics and Outcomes 
      Research (ISPOR). Published by Elsevier Inc. All rights reserved.
FAU - Argenta, Catia
AU  - Argenta C
AD  - Graduate Program in Medical Sciences, Universidade Federal do Rio Grande do Sul, 
      Porto Alegre, Brazil.
FAU - Ferreira, Maria Angelica Pires
AU  - Ferreira MA
FAU - Sander, Guilherme Becker
AU  - Sander GB
FAU - Moreira, Leila Beltrami
AU  - Moreira LB
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Value Health
JT  - Value in health : the journal of the International Society for Pharmacoeconomics 
      and Outcomes Research
JID - 100883818
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/administration & dosage/adverse effects/*economics
MH  - Blood Coagulation/drug effects
MH  - Blood Transfusion/economics
MH  - Brazil
MH  - Chi-Square Distribution
MH  - Cost Savings
MH  - Drug Administration Schedule
MH  - *Drug Costs
MH  - Drug Monitoring/economics
MH  - Enoxaparin/administration & dosage/adverse effects/*economics
MH  - Health Resources/*economics/statistics & numerical data
MH  - Health Services Research
MH  - Hemorrhage/chemically induced/economics/therapy
MH  - Heparin/administration & dosage/adverse effects/*economics
MH  - *Hospital Costs
MH  - Hospitalization/*economics
MH  - Hospitals, Teaching/economics
MH  - Humans
MH  - Logistic Models
MH  - Middle Aged
MH  - Models, Economic
MH  - Outcome and Process Assessment, Health Care/*economics
MH  - Prospective Studies
MH  - Recurrence
MH  - Time Factors
MH  - Treatment Outcome
MH  - Venous Thromboembolism/blood/drug therapy/*economics/mortality
MH  - Young Adult
EDAT- 2011/08/24 06:00
MHDA- 2011/10/15 06:00
CRDT- 2011/08/16 06:00
PHST- 2011/08/16 06:00 [entrez]
PHST- 2011/08/24 06:00 [pubmed]
PHST- 2011/10/15 06:00 [medline]
AID - S1098-3015(11)01433-1 [pii]
AID - 10.1016/j.jval.2011.05.017 [doi]
PST - ppublish
SO  - Value Health. 2011 Jul-Aug;14(5 Suppl 1):S89-92. doi: 10.1016/j.jval.2011.05.017.